Document Detail

Effects of a randomized controlled trial of transcendental meditation on components of the metabolic syndrome in subjects with coronary heart disease.
MedLine Citation:
PMID:  16772250     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: The metabolic syndrome is thought to be a contributor to coronary heart disease (CHD), and components of the syndrome have been identified as possible therapeutic targets. Previous data implicate neurohumoral activation related to psychosocial stress as a contributor to the metabolic syndrome. The aim of this study was to evaluate the efficacy of transcendental meditation (TM) on components of the metabolic syndrome and CHD. METHODS: We conducted a randomized, placebo-controlled clinical trial of 16 weeks of TM or active control treatment (health education), matched for frequency and time, at an academic medical center in a total of 103 subjects with stable CHD. Main outcome measures included blood pressure, lipoprotein profile, and insulin resistance determined by homeostasis model assessment (calculated as follows: [(fasting plasma glucose level [in milligrams per deciliter] x fasting plasma insulin level [in microunits per milliliter]) x 0.0552]/22.5); endothelial function measured by brachial artery reactivity testing; and cardiac autonomic system activity measured by heart rate variability. RESULTS: The TM group had beneficial changes (measured as mean +/- SD) in adjusted systolic blood pressure (-3.4 +/- 2.0 vs 2.8 +/- 2.1 mm Hg; P = .04), insulin resistance (-0.75 +/- 2.04 vs 0.52 +/- 2.84; P = .01), and heart rate variability (0.10 +/- 0.17 vs -0.50 +/- 0.17 high-frequency power; P = .07) compared with the health education group, respectively. There was no effect of brachial artery reactivity testing. CONCLUSIONS: Use of TM for 16 weeks in CHD patients improved blood pressure and insulin resistance components of the metabolic syndrome as well as cardiac autonomic nervous system tone compared with a control group receiving health education. These results suggest that TM may modulate the physiological response to stress and improve CHD risk factors, which may be a novel therapeutic target for the treatment of CHD.
Maura Paul-Labrador; Donna Polk; James H Dwyer; Ivan Velasquez; Sanford Nidich; Maxwell Rainforth; Robert Schneider; C Noel Bairey Merz
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural    
Journal Detail:
Title:  Archives of internal medicine     Volume:  166     ISSN:  0003-9926     ISO Abbreviation:  Arch. Intern. Med.     Publication Date:  2006 Jun 
Date Detail:
Created Date:  2006-06-14     Completed Date:  2006-08-04     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  0372440     Medline TA:  Arch Intern Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1218-24     Citation Subset:  AIM; IM    
Division of Cardiology, Department of Medicine, Cedars-Sinai Research Institute, Cedars-Sinai Medical Center, Los Angeles 90048, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Coronary Disease / complications*,  metabolism,  physiopathology
Metabolic Syndrome X / complications*,  metabolism,  physiopathology,  therapy*
Single-Blind Method
Grant Support
1-P50-AA0082-02/AA/NIAAA NIH HHS; 1-R15-HL660242-01/HL/NHLBI NIH HHS; M01-RR00425/RR/NCRR NIH HHS; R01 AT00226/AT/NCCAM NIH HHS; R01-HL51519-08/HL/NHLBI NIH HHS
Comment In:
Arch Intern Med. 2006 Dec 11-25;166(22):2553; author reply 2554   [PMID:  17159025 ]
Arch Intern Med. 2006 Dec 11-25;166(22):2553; author reply 2554   [PMID:  17159024 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosi...
Next Document:  Effects of a supervised home-based aerobic and progressive resistance training regimen in women infe...